Joseph V. Simone, MD, of the Simone Consulting Company, gives his expert perspective on the important messages of this year’s meeting.
Louis Burt Nabors, MD, of the University of Alabama at Birmingham Comprehensive Cancer Center, discusses improvements in the 2016 NCCN Guidelines for glioma, anaplastic oligodendroglioma, and glioblastoma.
Christopher Willett, MD, of Duke Cancer Center, discusses short and long courses of treatment, neoadjuvant chemotherapy with or without radiation, and organ preservation without surgery.
Alan Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new observations on biomarkers, the best combinations of therapies, and how to sequence them.
Douglas E. Wood, MD, of the University of Washington, discusses best practices, which enable a complete workup in 1 to 2 weeks in almost all patients, saving unnecessary testing.
Nadeem Abu-Rustum, MD, of Memorial Sloan Kettering Cancer Center, discusses improvements in fertility-sparing surgery for young women, advances in lymph node assessment, and the evolving role of chemotherapy and radiation.
